Norepinephrine genes predict response time variability and methylphenidate-induced changes in neuropsychological function in attention deficit hyperactivity disorder

Journal of Clinical Psychopharmacology

Volumn 33, Issue 3, 2013, Pages 356-362

  Kim, Bung Nyun ^a   Kim, Jae Won ^a   Cummins, Tarrant D R ^b   Bellgrove, Mark A ^b   Hawi, Ziarih ^b   Hong, Soon Beom ^a   Yang, Young Hui ^c   Kim, Hyo Jin ^a   Shin, Min Sup ^a   Cho, Soo Churl ^a   Kim, Ji Hoon ^c   Son, Jung Woo ^d   Shin, Yun Mi ^e   Chung, Un Sun ^f   Han, Doug Hyun ^g  

^a Seoul National University College of Medicine   (South Korea)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c Pusan National University Hospital   (South Korea)

^d Chungbuk National University Hospital   (South Korea)

^e Ajou University Medical Center   (South Korea)

^f Kyungpook National University Hospital   (South Korea)

^g Chung Ang University College of Medicine   (South Korea)

Author keywords

ADRA2A; attention deficit hyperactivity disorder; comprehensive attention test; methylphenidate response; norepinephrine; SLC6A2

Indexed keywords

ALPHA 2A ADRENERGIC RECEPTOR; METHYLPHENIDATE; NORADRENALIN; NORADRENALIN TRANSPORTER;

ALLELE; ARTICLE; ATTENTION; ATTENTION DEFICIT DISORDER; CHILD; CHILDHOOD DISEASE; DISEASE SEVERITY; FEMALE; GENETIC VARIABILITY; HUMAN; INTELLIGENCE QUOTIENT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESPONSE TIME; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DIAGNOSIS, COMPUTER-ASSISTED; FEMALE; HUMANS; MALE; METHYLPHENIDATE; NOREPINEPHRINE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RECEPTORS, ADRENERGIC, ALPHA-2; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84877585551     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31828f9fc3     Document Type: Article

References (36)

1. Faraone SV, Doyle AE. The nature and heritability of attention-deficit/ hyperactivity disorder. Child Adolesc Psychiatr Clin N Am. 2011; 10: 299-316, viii-i.x.
2. Centers for Disease Control and Prevention (CDC). Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among childrenVUnited States, 2003 and 2007. MMWR. 2010; 59: 1439-1443.
3. Pliszka SR, McCracken JT, Maas JW. Catecholamines in attention-deficit hyperactivity disorder: current perspectives. J Am Acad Child Adolesc Psychiatry. 1996; 35: 264-272.
4. Biederman J, Spencer T. Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry. 1999; 46: 1234-1242.
5. Arnsten AF. Stimulants: therapeutic actions in ADHD. Neuropsychopharmacology. 2006; 31: 2376-2383.
6. Greene CM, Bellgrove MA, Gill M, et al. Noradrenergic genotype predicts lapses in sustained attention. Neuropsychologia. 2009; 47: 591-594.
7. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet. 2005; 366: 237-248.
8. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003; 53: 112-120.
9. Spencer T, Biederman J, Wilens T, et al. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry. 1996; 35: 409-432.
10. Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res. 1998; 94: 127-152.
11. Han DD, Gu HH. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol. 2006; 6: 6.
12. Berridge CW, Devilbiss DM, Andrzejewski ME, et al. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry. 2006; 60: 1111-1120.
13. Andrews GD, Lavin A. Methylphenidate increases cortical excitability via activation of alpha-2 noradrenergic receptors. Neuropsychopharmacology. 2006; 31: 594-601.
14. Lario S, Calls J, Cases A, et al. MspI identifies a biallelic polymorphism in the promoter region of the alpha 2A-adrenergic receptor gene. Clin Genet. 1997; 51: 129-130.
15. Hoehe MR, Berrettini WH, Lentes KU. DraI identifies a two allele DNA polymorphism in the human alpha 2-adrenergic receptor gene (ADRAR), using a 5.5 kb probe (p ADRAR). Nucleic Acids Res. 1988; 16: 9070.
16. Belfer I, Buzas B, Hipp H, et al. Haplotype-based analysis of alpha 2A, 2B, and 2C adrenergic receptor genes captures information on common functional loci at each gene. J Hum Genet. 2005: 50: 12-20.
17. Kim BN, Kim JW, Kang H, et al. Regional differences in cerebral perfusion associated with the alpha-2A-adrenergic receptor genotypes in attention deficit hyperactivity disorder. J Psychiatry Neurosci. 2010; 35: 330-336.
18. Kim CH, Hahn MK, Joung Y, et al. A polymorphism in the norepinephrine transporter gene alters promoter activity and is associated with attention-deficit hyperactivity disorder. Proc Natl Acad Sci U S A. 2006; 103: 19164-19169.
19. Yang L, Wang YF, Li J, et al. Association of norepinephrine transporter gene with methylphenidate response. J Am Acad Child Adolesc Psychiatry. 2004; 43: 1154-1158.
20. Llorente AM, Voigt RG, Jensen CL, et al. Performance on a visual sustained attention and discrimination task is associated with urinary excretion of norepinephrine metabolite in children with attention-deficit/hyperactivity disorder (AD/HD). Clin Neuropsychol. 2006; 20: 133-144.
21. Cho SC, Kim JW, Kim BN, et al. Possible association of the alpha-2A-adrenergic receptor gene with response time variability in attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet. 2008; 147B: 957-963.
22. Castellanos FX, Tannock R. Neuroscience of attention-deficit/ hyperactivity disorder: the search for endophenotypes. Nat Rev Neurosci. 2002; 3: 617-628.
23. Doyle AE, Faraone SV, Seidman LJ, et al. Are endophenotypes based on measures of executive functions useful for molecular genetic studies of ADHD? J Child Psychol Psychiatry. 2005; 46: 774-803.
24. Kaufman J, Birmaher B, Brent D, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997; 36: 980-988.
25. Kim YS, Cheon KA, Kim BN, et al. The reliability and validity of Kiddie-Schedule for Affective Disorders and Schizophrenia-Present and Lifetime VersionYKorean version (K-SADS-PL-K). Yonsei Med J. 2004; 45: 81-89.
26. DuPaul GJ. Parent and teacher ratings of ADHD symptomsVpsychometric properties in a community-based sample. J Clin Child Psychol. 1991; 20: 245-253.
27. So YK, Noh JS, Kim YS, et al. The reliability and validity of Korean parent and teacher ADHD Rating Scale. J Korean Neuropsychiatr Assoc. 2002; 41: 283-289.
28. Yoo HK, Lee JS, Kang SH, et al. Standardization of the Comprehensive Attention Test for the Korean children and adolescents. J Kor Acad Child Adolesc Psychiatry. 2009; 20: 68-75.
29. Tabachnick BG, Fidell LS. Using Multivariate Statistics. 5th ed. Boston, MA: Allyn and Bacon; 2007.
30. Sole X, Guino E, Valls J, et al. SNPstats: a Web tool for the analysis of association studies. Bioinformatics. 2006; 22: 1928-1929.
31. Nyholt DR. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet. 2004; 74: 765-769.
32. Cheverud JM. A simple correction for multiple comparisons in interval mapping genome scans. Heredity. 2001; 87: 52-58.
33. Li J, Ji L. Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity. 2005; 95: 221-227.
34. Bellgrove MA, Hester R, Garavan H. The functional neuroanatomical correlates of response variability: evidence from a response inhibition task. Neuropsychologia. 2004; 42: 1910-1916.
35. Frank MJ, Santamaria A, O'Reilly RC, et al. Testing computational models of dopamine and noradrenaline dysfunction in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2007; 32: 1583-1599.
36. Kollins SH, Anastopoulos AD, Lachiewicz AM, et al. SNPs in dopamine D2 receptor gene (DRD2) and norepinephrine transporter gene (NET) are associated with continuous performance task (CPT) phenotypes in ADHD children and their families. Am J Med Genet B Neuropsychiatr Genet. 2008; 147B: 1580-1588.